The role of miRNAs in cutaneous squamous cell carcinoma

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 1, 2016, Pages 3-9

  Yu, Xin ^a   Li, Zheng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Cutaneous squamous cell carcinoma; MicroRNAs; MiR; Oncogene

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 124; MICRORNA 155; MICRORNA 193B; MICRORNA 199A; MICRORNA 205; MICRORNA 21; MICRORNA 31; MICRORNA 34A; MICRORNA 361 5P; MICRORNA 365; MICRORNA 365A; MICRORNA 483 3P; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER GROWTH; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DOWN REGULATION; HUMAN; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN CARCINOGENESIS; SKIN CARCINOMA; UPREGULATION; ANIMAL; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; RNA INTERFERENCE; SKIN NEOPLASMS;

EID: 84956581346     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12649     Document Type: Review

References (86)

1. Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest. 2012; 122: 464-72.
2. Hussain SK, Sundquist J, Hemminki K. Incidence trends of squamous cell and rare skin cancers in the Swedish national cancer registry point to calendar year and age-dependent increases. J Invest Dermatol. 2010; 130: 1323-8.
3. Pfaff D, Philippova M, Buechner SA, et al. T-cadherin loss induces an invasive phenotype in human keratinocytes and squamous cell carcinoma (SCC) cells in vitro and is associated with malignant transformation of cutaneous SCC in vivo. Br J Dermatol. 2010; 163: 353-63.
4. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001; 344: 975-83.
5. Runger TM. Role of UVA in the pathogenesis of melanoma and non-melanoma skin cancer. A short review. Photodermatol Photoimmunol Photomed. 1999; 15: 212-6.
6. Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist. 2010; 15: 1320-8.
7. Wells JL 3rd, Shirai K. Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipients. Am J Clin Oncol. 2012; 35: 498-503.
8. Yu X, Li Z, Liu J. MiRNAs in primary cutaneous lymphomas. Cell Prolif. 2015; 48: 271-7.
9. Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis. Int J Mol Med. 2014; 34: 923-33.
10. Yu X, Li Z, Shen J, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through RhoC-Akt pathway by targeting HOXD10 in intervetebral disc degeneration. PLoS ONE. 2013; 8: e83080.
11. Yu X, Li Z, Wu WK. MicroRNA-10b induces vascular muscle cell proliferation through Akt pathway by targeting TIP30. Curr Vasc Pharmacol. 2015. [Epub ahead of print].
12. Li Z, Yu X, Shen J, et al. MicroRNA expression and its clinical implications in Ewing's sarcoma. Cell Prolif. 2015; 48: 1-6.
13. Li D, Yang P, Li H, et al. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci. 2012; 91: 440-7.
14. Hudson RS, Yi M, Esposito D, et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 2012; 40: 3689-703.
15. Nohata N, Hanazawa T, Enokida H, et al. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget. 2012; 3: 9-21.
16. Tominaga E, Yuasa K, Shimazaki S, et al. MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. Exp Cell Res. 2013; 319: 77-88.
17. Nohata N, Sone Y, Hanazawa T, et al. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget. 2011; 2: 29-42.
18. Yoshino H, Enokida H, Chiyomaru T, et al. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res Commun. 2012; 417: 588-93.
19. Yamasaki T, Yoshino H, Enokida H, et al. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol. 2012; 40: 1821-30.
20. Yan D, Dong Xda E, et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem. 2009; 284: 29596-604.
21. Reid JF, Sokolova V, Zoni E, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res. 2012; 10: 504-15.
22. Fleming JL, Gable DL, Samadzadeh-Tarighat S, et al. Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice. PeerJ. 2013; 1: e68.
23. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010; 17: 193-9.
24. Lefort K, Brooks Y, Ostano P, et al. A miR-34a-SIRT6 axis in the squamous cell differentiation network. EMBO J. 2013; 32: 2248-63.
25. Mondanizadeh M, Arefian E, Mosayebi G, et al. MicroRNA-124 regulates neuronal differentiation of mesenchymal stem cells by targeting Sp1 mRNA. J Cell Biochem. 2015; 116: 943-53.
26. Furuta M, Kozaki KI, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010; 31: 766-76.
27. Hunt S, Jones AV, Hinsley EE, et al. MicroRNA-124 suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS Lett. 2011; 585: 187-92.
28. Liu X, Sempere LF, Galimberti F, et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009; 15: 1177-83.
29. Zhang T, Wang J, Zhai X, et al. MiR-124 retards bladder cancer growth by directly targeting CDK4. Acta Biochim Biophys Sin. 2014; 46: 1072-9.
30. Zheng F, Liao YJ, Cai MY, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012; 61: 278-89.
31. Penna E, Orso F, Taverna D. miR-214 as a key hub that controls cancer networks: small player, multiple functions. J Invest Dermatol. 2015; 135: 960-9.
32. Yamane K, Jinnin M, Etoh T, et al. Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med. 2013; 91: 69-81.
33. Henson BJ, Bhattacharjee S, O'Dee DM, et al. Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosom Cancer. 2009; 48: 569-82.
34. Liu LH, Li H, Li JP, et al. miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem Biophys Res Commun. 2011; 416: 31-8.
35. Huang L, Luo J, Cai Q, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer. 2011; 128: 1758-69.
36. Wu D, Ding J, Wang L, et al. microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett. 2013; 5: 829-34.
37. Zhang Y, Yan LX, Wu QN, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011; 71: 3552-62.
38. Shi XB, Xue L, Yang J, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA. 2007; 104: 19983-8.
39. Xu N, Zhang L, Meisgen F, et al. MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J Biol Chem. 2012; 287: 29899-908.
40. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA. 2009; 106: 2735-40.
41. O'Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 2007; 104: 1604-9.
42. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA. 2006; 103: 7024-9.
43. Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science. 2007; 316: 604-8.
44. Zhang J, Cheng C, Yuan X, et al. microRNA-155 acts as an oncogene by targeting the tumor protein 53-induced nuclear protein 1 in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7: 602-10.
45. Zhou J, Wang W, Gao Z, et al. MicroRNA-155 promotes glioma cell proliferation via the regulation of MXI1. PLoS ONE. 2013; 8: e83055.
46. Higgs G, Slack F. The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma. 2013; 3: 17.
47. Huffaker TB, Hu R, Runtsch MC, et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep. 2012; 2: 1697-709.
48. Zonari E, Pucci F, Saini M, et al. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood. 2013; 122: 243-52.
49. Mariani L, Monfulleda N, Alemany L, et al. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. BMC Cancer. 2010; 10: 259.
50. Chen J, Feilotter HE, Pare GC, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010; 176: 2520-9.
51. Xu C, Liu S, Fu H, et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer. 2010; 46: 2828-36.
52. Kang SM, Lee HJ, Cho JY. MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer. Cancer Lett. 2013; 335: 487-94.
53. Nie J, Liu L, Zheng W, et al. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2012; 33: 220-5.
54. Gastaldi C, Bertero T, Xu N, et al. miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma. Carcinogenesis. 2014; 35: 1110-20.
55. Kanitz A, Imig J, Dziunycz PJ, et al. The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. PLoS ONE. 2012; 7: e49568.
56. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189-98.
57. Lee JW, Choi CH, Choi JJ, et al. Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res. 2008; 14: 2535-42.
58. Wang Z, Ma X, Cai Q, et al. MiR-199a-3p promotes gastric cancer progression by targeting ZHX1. FEBS Lett. 2014; 588: 4504-12.
59. He XJ, Ma YY, Yu S, et al. Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho. BMC Cancer. 2014; 14: 218.
60. Wang SH, Zhou JD, et al. MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells. Int J Clin Exp Pathol. 2014; 7: 7131-41.
61. Bowden J, Brennan PA, Umar T, et al. Expression of vascular endothelial growth factor in basal cell carcinoma and cutaneous squamous cell carcinoma of the head and neck. J Cutan Pathol. 2002; 29: 585-9.
62. Detmar M, Velasco P, Richard L, et al. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol. 2000; 156: 159-67.
63. Sauter ER, Nesbit M, Watson JC, et al. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 1999; 5: 775-82.
64. Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer. 1997; 76: 930-4.
65. Hao J, Zhang S, Zhou Y, et al. MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer. FEBS Lett. 2011; 585: 207-13.
66. Abue M, Yokoyama M, Shibuya R, et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol. 2015; 46: 539-47.
67. Veronese A, Lupini L, Consiglio J, et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res. 2010; 70: 3140-9.
68. Bertero T, Bourget-Ponzio I, Puissant A, et al. Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties. Cell Cycle. 2013; 12: 2183-93.
69. Motoyama K, Inoue H, Mimori K, et al. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol. 2010; 36: 1089-95.
70. Chang KH, Miller N, Kheirelseid EA, et al. MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur J Surg Oncol. 2011; 37: 597-603.
71. Ribas J, Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle. 2010; 9: 923-9.
72. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010; 70: 4528-38.
73. Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 2011; 30: 407-14.
74. Tran N, McLean T, Zhang X, et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun. 2007; 358: 12-7.
75. Dziunycz P, Iotzova-Weiss G, Eloranta JJ, et al. Squamous cell carcinoma of the skin shows a distinct microRNA profile modulated by UV radiation. J Invest Dermatol. 2010; 130: 2686-9.
76. Darido C, Georgy SR, Wilanowski T, et al. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell. 2011; 20: 635-48.
77. Li X, Huang K, Yu J. Inhibition of microRNA-21 upregulates the expression of programmed cell death 4 and phosphatase tensin homologue in the A431 squamous cell carcinoma cell line. Oncol Lett. 2014; 8: 203-7.
78. Zheng W, Liu Z, Zhang W, et al. miR-31 functions as an oncogene in cervical cancer. Arch Gynecol Obstet. 2015; 292: 1083-9.
79. Dong Z, Zhong Z, Yang L, et al. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 2014; 343: 249-57.
80. Kim HS, Lee KS, Bae HJ, et al. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget. 2015; 6: 8089-102.
81. Laurila EM, Kallioniemi A. The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosom Cancer. 2013; 52: 1103-13.
82. Wang A, Landen NX, Meisgen F, et al. MicroRNA-31 is overexpressed in cutaneous squamous cell carcinoma and regulates cell motility and colony formation ability of tumor cells. PLoS ONE. 2014; 9: e103206.
83. Yu J, Ryan DG, Getsios S, et al. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci USA. 2008; 105: 19300-5.
84. Guo L, Huang ZX, Chen XW, et al. Differential expression profiles of microRNAs in NIH3T3 cells in response to UVB irradiation. Photochem Photobiol. 2009; 85: 765-73.
85. Zhou M, Zhou L, Zheng L, et al. miR-365 promotes cutaneous squamous cell carcinoma (CSCC) through targeting nuclear factor I/B (NFIB). PLoS ONE. 2014; 9: e100620.
86. Zhou M, Liu W, Ma S, et al. A novel onco-miR-365 induces cutaneous squamous cell carcinoma. Carcinogenesis. 2013; 34: 1653-9.